Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8,767 INR | +1.50% | -0.74% | +8.68% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.27 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.68% | 2.38B | B- | ||
+15.37% | 41.97B | B- | ||
+22.56% | 22.34B | B+ | ||
+14.89% | 15.25B | - | ||
+16.53% | 14B | B+ | ||
+49.78% | 12.06B | B | ||
-10.77% | 6.8B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+14.18% | 5.49B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- SANOFI Stock
- Ratings Sanofi India Limited